NCT05007353: SINGER

The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) Study

Status unknown NA Last updated 24 August 2021

What this trial tests

NA trial testing Structured Lifestyle Intervention in Cognitive Impairment in 1,200 participants. Status unknown.

Timeline

23 August 2021

Primary endpoint
31 December 2025

31 January 2026

Quick facts

Lead sponsor	National University of Singapore
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	1,200
Start date	23 August 2021
Primary completion	31 December 2025
Estimated completion	31 January 2026
Sites	3 locations across Singapore

Drugs / interventions tested

• Structured Lifestyle Intervention
• Self-Guided Intervention

Conditions studied

• Cognitive Impairment — all drugs for Cognitive Impairment →
• Alzheimer Disease — all drugs for Alzheimer Disease →
• Vascular Cognitive Impairment — all drugs for Vascular Cognitive Impairment →
• Dementia — all drugs for Dementia →

Sponsor

National University of Singapore

Who can join

Adults 60 to 77, any sex, with Cognitive Impairment or Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study in Finland found that a multidomain intervention of physical activity, nutritional guidance, cognitive training, social activities and management of vascular risk factors slowed cognitive decline in healthy older adults at increased risk of cognitive decline. A 6-month pilot study was initiated in Singapore, which demonstrated the cultural feasibility and practicality of the FINGER interventions and a set of locally adapted interventions in an Asian population. The SINGER study is a 2-year randomized controlled trial that aims to test the efficacy and safety of these lifestyle changes, including diet and cardiovascular risk factor management, cognitive and physical exercises, in delaying cognitive decline in older adults at risk of dementia.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. An Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases.
   Teleanu DM, Niculescu AG, Lungu II, Radu CI, et al · · 2022 · cited 672× · PMID 35682615 · DOI 10.3390/ijms23115938
2. Longer scans boost prediction and cut costs in brain-wide association studies.
   Ooi LQR, Orban C, Zhang S, Nichols TE, et al · · 2025 · cited 33× · PMID 40670782 · DOI 10.1038/s41586-025-09250-1
3. The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER): Study Design and Protocol.
   Xu X, Chew KA, Wong ZX, Phua AKS, et al · · 2022 · cited 26× · PMID 35098972 · DOI 10.14283/jpad.2022.5
4. Canadian Stroke Best Practice Recommendations: Vascular cognitive impairment, 7th edition practice guidelines update, 2024.
   Swartz RH, Longman RS, Lindsay MP, Lund R, et al · · 2025 · cited 12× · PMID 39822128 · DOI 10.1002/alz.14324
5. Heart-Brain Axis: Subclinical Cardiovascular Changes and Brain Health.
   Habibi P, Chen LY, Sorond FA, Shroff GR, et al · · 2026 · cited 2× · PMID 41614273 · DOI 10.1161/jaha.125.047458
6. Baseline characteristics of the SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER) multidomain dementia prevention randomized controlled trial and insights from the recruitment process.
   Yap KH, Chen C, Chong EJY, Kandiah N, et al · · 2026 · PMID 41943481 · DOI 10.1002/alz.71313
7. Retinal manifestations and their diagnostic significance in Alzheimer's disease.
   Abhyankar SD, Little K, Stitt A, Bhatwadekar AD. · · 2025 · PMID 40799319 · DOI 10.1177/25424823251361937